LFVN Lifevantage

INVESTOR ALERT: Khang & Khang LLP Announces an Investigation of LifeVantage Corporation and Reminds Investors with Losses to Contact the Firm

Khang & Khang LLP (the “Firm”) announces that it is investigating claims against LifeVantage Corporation (“LifeVantage” or the “Company”) (Nasdaq: LFVN) concerning possible violations of federal securities laws.

If you purchased shares of LifeVantage and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].

The investigation focuses on the Company’s announcement on September 13, 2016 that it would delay the release of its fourth quarter and fiscal year 2016 financial results. The reason for the delay is for LifeVantage to carry out an internal review of sales into certain international markets and the revenue and income tax associated with those sales. The Company stated that it is unable to estimate the impact of the review to net revenue, tax expense, net income or other aspects of its financial statements for the fiscal year ended June 30, 2016 or any potential prior periods. When this news was announced, shares of LifeVantage decreased in value.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].

This press release may constitute Attorney Advertising in some jurisdictions.

EN
15/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lifevantage

 PRESS RELEASE

LifeVantage To Open Iceland Market

LifeVantage To Open Iceland Market Launch delivers innovative business opportunity and top wellness products to Iceland, marking a bold step in European expansion SALT LAKE CITY, July 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced its upcoming launch into Iceland expected in September. This marks the company’s continued partnership with its field leadership on international expansion and reinforces its commitment to delivering science-backed wellness so...

 PRESS RELEASE

LifeVantage Announces Expanded Human Clinical Study for MindBody GLP-1...

LifeVantage Announces Expanded Human Clinical Study for MindBody GLP-1 System™; Findings Increase Average in Natural GLP-1 Production to Over 200%‡‡ Expanded U.S.-clinical research study shows strong results including increased fat loss, improved cravings control, and healthier body composition*‡ SALT LAKE CITY, July 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced new results from its second human clinical study on the , revealing even more compelling ou...

 PRESS RELEASE

LifeVantage Hosts Activate 2025, Unveils New Quarterly Business Campai...

LifeVantage Hosts Activate 2025, Unveils New Quarterly Business Campaign and Incentive to Drive Global Growth SALT LAKE CITY, July 15, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, held its global Activate 2025 virtual event on Saturday, July 12. The event, supported by Consultant-hosted watch parties and local in-person gatherings, provided a dynamic platform to inspire Consultant business engagement and growth. Activate 2025 also celebrated innovation, reinforcing LifeVan...

 PRESS RELEASE

LifeVantage Declares Quarterly Dividend

LifeVantage Declares Quarterly Dividend SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company’s Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid June 13, 2025 to all stockholders of record at the close of business on May 30, 2025. This represents an increase in the dividend amount by 12.5% over the previous quarter. About LifeVantage Corpo...

 PRESS RELEASE

LifeVantage Announces Financial Results for the Third Quarter of Fisca...

LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2025 SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2025. Third Quarter Fiscal 2025 Summary*: Revenue was $58.4 million, an increase of 21.1% from the prior year period. Excluding the negative impact of foreign currency fluctuations, third quarter revenue increased approximat...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch